EGFR and skin squamous cell carcinoma: In recent years, novel therapies, including immune checkpoint inhibitors and EGFR inhibitors, have demonstrated promising results for the treatment of cSCC, particularly in unresectable or recurrent/metastatic disease (Table 3).